You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Accommodation integrated technology to minimize the impact of disability on students' assessment

    SBC: 3-C Institute for Social Development, Inc.            Topic: N/A

    There is growing interest in computerized systems to increase accessibility of assessments for students with disabilities. Technology offers an ideal platform for implementing Universal Design (UD) principles for assessment to better accommodate student diversity and support broad student participation. The goal of this Phase II SBIR project is to continue the research and development of Assess2Pr ...

    SBIR Phase II 2014 Department of Education
  2. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. CONTRACT # N44CO-2014-00003C P.O.P. 5/15/2014-5/14/2015; IND ENABLING DEVELOPMENT OF NANOGMP: TARGETED; PURPOSE: TO PROVIDE FY14 FUNDING FOR SBIR PHASE II AWARD

    SBC: QUALIBER, INC.            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. IGF::OT::IGF SBIR Topic 314 Phase II- 3D Human Tumor Co-culture System for Accurate Prediction of Clinical Efficacy.

    SBC: KIYATEC, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Arise: An Online Relapse Prevention Tool for Substance Abusers

    SBC: 3-C Institute for Social Development, Inc.            Topic: NIDA

    Modify Phase I product and develop the full Arise product. Modify initial prototype based on feedback and fully develop all six modules. PUBLIC HEALTH RELEVANCE

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Therapeutic for Invasive Candidiasis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Systemic fungal infections are increasingly common, especially in immune compromised patients. While new antifungal drugs have been developed, there is still a high mortality associated with these infections, especiallythose due to Candida albicans, other non-albicans species (NAS). This is due to the limited spectrum of the drugs, significant side effects, as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: NIDDK

    Project Summary/Abstract According to the ADA, 25.8 million children and adults have diabetes. Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing. A major cause of morbidity and hospitalizationis diabetic foot ulceration (DFUs) that may result in infection, gangrene, amputations requiring prolonged hospitalization, costly treatments, an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development and Utilization of a Novel Aerosol-Generating Technology to Deliver Luc

    SBC: DISCOVERY LABORATORIES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Respiratory distress syndrome (RDS) is an acute, severe pulmonary disorder that is the leading cause of morbidity and mortality in preterm infants. It is a major healthcare concern - costs associated with treatment of RDS and its complications exceed 2.4 billion annually in the US. Currently, animal-derived surfactants instilled intratracheally via an endotrac ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Infection resistant surface for ventricular assist device (VAD) transcutaneous dr

    SBC: ENSION Inc            Topic: NHLBI

    DESCRIPTION (provided by applicant): Infection is a common and frequently very serious complication associated with medical implants. Man-made materials, including those used to fabricate ventricular assist devices (VADs), compromise the body's ability tofight infection in tw ways. First, by breaching skin with transcutaneous cannulae and drivelines, and second, by eliciting a foreign body re ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government